Wall Street Zen Downgrades Illumina (NASDAQ:ILMN) to Hold

Illumina (NASDAQ:ILMN) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages have also weighed in on ILMN. Guggenheim raised their price objective on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Barclays increased their price target on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Canaccord Genuity Group upped their price objective on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Finally, JPMorgan Chase & Co. upgraded shares of Illumina from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $185.00 in a research report on Wednesday, June 10th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $156.88.

Illumina Stock Performance

ILMN stock opened at $186.65 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina has a 1-year low of $88.00 and a 1-year high of $196.66. The business has a 50 day simple moving average of $166.44 and a two-hundred day simple moving average of $143.40. The company has a market capitalization of $28.24 billion, a price-to-earnings ratio of 33.94, a PEG ratio of 3.49 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the business posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts anticipate that Illumina will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Scott M. Davies sold 615 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. The trade was a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Institutional investors have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Illumina by 7.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC boosted its position in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the last quarter. Elevation Wealth Partners LLC boosted its position in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares in the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.